Effect of experimental diabetes on pharmacokinetic parameters of lidocaine and MEGX in rats.

The aim of the study was to evaluate the effect of experimental diabetes on pharmacokinetic parameters of lidocaine and its metabolite monoethyl-glycylxylidide (MEGX) after a single intravenous administration in rats. The study was performed on male Wistar rats, randomized into 2 groups: group I--control animals and group II--animals with experimental diabetes induced by streptozotocin. Evaluation of lidocaine pharmacokinetics was performed 10 days after streptozotocin administration. Lidocaine concentrations were lower in rats with experimental diabetes compared with the values in the control group. In rats with diabetes, the shorter phase of distribution and faster drug elimination has been observed. During the pharmacokinetic study, the dynamic reduction of lidocaine concentration was accompanied by the increase in MEGX concentration in blood. Drug elimination rate constant (gammaz) increased by 68% in rats with experimental diabetes which had an effect on the shortening of lidocaine half-life in those animals (t1/2 by 39%) and on the increase in absolute clearance (CL) to 1.46 l/h comparing to control group (0.95 l/h), i.e. by 54%. The distribution rate constant of lidocaine (gamma1) was significantly greater in the animals with experimental diabetes (by 138%). The volume of distribution (Vd) in those animals decreased by 30% in comparison with the control group. The area under the plasma concentration-time curve (AUC) decreased by 48% in rats with experimental diabetes. The MEGX half-life (t1/2) increased from 0.34 h in the control group to 0.89 h in the rats with diabetes, i.e. by 165%. It reflects the impaired MEGX elimination in experimental diabetes. The results suggest that experimental diabetes can have an effect on lidocaine pharmacokinetics towards enhanced lidocaine elimination with accompanied increase in its metabolite (MEGX) concentration.

[1]  P. Meredith,et al.  The pharmacokinetics and pharmacodynamics of lignocaine and MEGX in healthy subjects , 1987, Journal of Pharmacokinetics and Biopharmaceutics.

[2]  F. Jamali,et al.  Effect of Experimental Diabetes Mellitus and Arthritis on the Pharmacokinetics of Hydroxychloroquine Enantiomers in Rats , 1998, Pharmaceutical Research.

[3]  T. Terasaki,et al.  Effect of Receptor Up-Regulation on Insulin Pharmacokinetics in Streptozotocin-Treated Diabetic Rats , 1991, Pharmaceutical Research.

[4]  M. Droździk,et al.  Metabolism of lidocaine by liver microsomes from streptozotocin-diabetic rats. , 2003, Polish journal of pharmacology.

[5]  R. Testa,et al.  The monoethylglycinexylidide test does not impair psychometric performance in patients with chronic hepatitis or cirrhosis. , 2000, Therapeutic drug monitoring.

[6]  J. S. Wang,et al.  Fluvoxamine is a more potent inhibitor of lidocaine metabolism than ketoconazole and erythromycin in vitro. , 1999, Pharmacology & toxicology.

[7]  J. M. Pratt,et al.  The P450 catalytic cycle and oxygenation mechanism. , 1998, Drug metabolism reviews.

[8]  K. Higaki,et al.  Short Communication Pharmacokinetics of Recombinant Human Insulin-Like Growth Factor-I in Diabetic Rats , 1997 .

[9]  K. Higaki,et al.  Developmental changes in pharmacokinetics of recombinant human insulin-like growth factor-I in rats. , 1997, Research communications in molecular pathology and pharmacology.

[10]  S. Imaoka,et al.  Changes in amounts of cytochrome P450 isozymes and levels of catalytic activities in hepatic and renal microsomes of rats with streptozocin-induced diabetes. , 1993, Biochemical pharmacology.

[11]  J. Potter,et al.  High-performance liquid chromatographic method for the simultaneous determination of monoethylglycinexylidide and lignocaine. , 1992, Journal of chromatography.

[12]  L. L. Miller,et al.  Effects of streptozotocin diabetes in the rat on blood levels of ten specific plasma proteins and on their net biosynthesis by the isolated perfused liver , 1990, Hepatology.

[13]  J. Schenkman,et al.  Effects of testosterone and growth hormone treatment on hepatic microsomal P450 expression in the diabetic rat. , 1990, Molecular pharmacology.

[14]  Imaoka Susumu,et al.  Metabolism of lidocaine by purified rat liver microsomal cytochrome P-450 isozymes. , 1989 .

[15]  S. Imaoka,et al.  Metabolism of lidocaine by purified rat liver microsomal cytochrome P-450 isozymes. , 1989, Biochemical pharmacology.

[16]  G. Kearns,et al.  Protein binding of phenytoin and lidocaine in pediatric patients with type I diabetes mellitus. , 1988, Developmental pharmacology and therapeutics.

[17]  P. Fratino,et al.  Serum Protein Binding of Phenytoin and Valproic Acid in Insulin‐Dependent Diabetes Mellitus , 1987, Therapeutic drug monitoring.

[18]  F. Belpaire,et al.  Influence of enhanced alpha-1-acid glycoprotein concentration on protein binding, pharmacokinetics and antiarrhythmic effect of lidocaine in the dog. , 1987, The Journal of pharmacology and experimental therapeutics.

[19]  R. T. Coutts,et al.  In vivo metabolism of lidocaine in the rat. Isolation of urinary metabolites as pentafluorobenzoyl derivatives and their identification by combined gas chromatography-mass spectrometry. , 1987, Journal of chromatography.

[20]  R. Kawai,et al.  Simultaneous quantitation of lidocaine and its four metabolites by high-performance liquid chromatography: application to studies on in vitro and in vivo metabolism of lidocaine in rats. , 1985, Journal of pharmaceutical sciences.

[21]  G. Sunahara,et al.  Differential effects of diabetes on microsomal metabolism of various substrates. Comparison of streptozotocin and spontaneously diabetic Wistar rats. , 1983, Biochemical pharmacology.

[22]  N. Kaplowitz.  Physiological significance of glutathione S-transferases. , 1980, The American journal of physiology.

[23]  K. Leibman,et al.  Effect of experimental diabetes on drug metabolism in the rat. , 1977, Drug metabolism and disposition: the biological fate of chemicals.

[24]  N. Finlayson,et al.  Antipyrine, paracetamol, and lignocaine elimination in chronic liver disease. , 1977, British medical journal.

[25]  Grant R. Wilkinson,et al.  A physiological approach to hepatic drug clearance , 1975 .

[26]  C. Difazio,et al.  Lidocaine Metabolism in Normal and Phenobarbital-pretreated Dogs , 1972, Anesthesiology.

[27]  R. Kato,et al.  Species and sex differences in aminopyrine N-demethylating activity of liver microsomes under unphysiological conditions. , 1968, Japanese journal of pharmacology.

[28]  R. Kato,et al.  Sex differences in the effects of abnormal physiological states on the metabolism of drugs by rat liver microsomes. , 1965, The Journal of pharmacology and experimental therapeutics.